ArticleJournal of experimental & clinical cancer research : CR2022

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.

Chunyan Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.